AstraZeneca PLC (AZN) Competitors & Peers

The 5 companies closest to AstraZeneca PLC on the factors that matter — each comparable links to its own dossier. Numbers are code-computed, never estimated.

How we identify peers ↗

Ticker	Relationship	Price	Comparables
LLY	Peer	$1,231.94	P/E 39.8RSI 61Cap 1.10 T
JNJ	Peer	$261.81	P/E 30.4RSI 58Cap 630.9 B
ABBV	Peer	$247.97	P/E 69.5RSI 50Cap 438.2 B
MRK	Peer	$130.92	P/E 103.1RSI 60Cap 323.0 B
NVS	Peer	$156.79	P/E 23.6RSI 55Cap 298.0 B

How these relationships were derived

Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.

Confirmed relationships (cited)

Sourced from a public filing or disclosure — each links to its origin.

RIGLSupplier
Own 10-K customer-concentration disclosure: AstraZenecaAB = 100% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗
NKTRSupplier
Own 10-K customer-concentration disclosure: AstraZeneca = 29% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗
MRNASupplier
Own 10-K customer-concentration disclosure: AstraZeneca = 34% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗
INOSupplier
Own 10-K customer-concentration disclosure: AstraZeneca = 2% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗

Model-inferred relationships (unverified)

Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.

DSNKYPartner
AZN + Daiichi Enhertu + datopotamab DXd-ADC collaboration.
Model-inferred, unverified — treat as a lead, not evidence
DSNKYPartner
AZN + Daiichi Enhertu + Datroway ADC collaboration.
Model-inferred, unverified — treat as a lead, not evidence
DNTHCompetitor
Dianthus' DNTH103 competes with AstraZeneca's Soliris/Ultomiris products.
Model-inferred, unverified — treat as a lead, not evidence